oral

Preclinical data on UCART20x22, Cellectis’ first allogeneic dual CAR T-cell product candidate to treat B-NHL, presented at an oral session Encouraging data presented on gene editing process using Cellectis TALEN® technology to develop…

- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, in ovarian cancer, demonstrating that FolRα-selected patients, who…

…

Worldwide, 3.5 billion people suffer from oral diseases, affecting 3 out of 4 individuals with tooth decay, gum diseases, or tooth loss. This prevalence continues to increase due to factors such as the availability of affordable high…

Data supported selection of EP262 as a potent, highly selective development candidate Clinical development of EP262 recently initiated as a novel treatment for a broad range of mast cell mediated diseases including chronic spontaneous…

<!-- Name:DistributionId Value:8754148 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value: -->…

DUBLIN--(BUSINESS WIRE)--The "New Zealand: HnB, Oral Tobacco and Nicotine Pouch Regulation" report has been added to ResearchAndMarkets.com's offering. This report offers a detailed overview of the current regulatory regime in place in…

PF-07081532 is the first clinical candidate from multi-target drug discovery collaboration to advance into Phase 2 trialsDosing of first subject in Phase 2 trial by Pfizer triggers payment of US$10 million to Sosei Heptares TOKYO…

SAN JOSE, Calif., Dec. 15, 2022 /PRNewswire/ -- Published Nov 25, 2022 in the highly respected peer-reviewed journal Phytotherapy Research, results show statistically significant reduction in duration of illness and severity scores of…

23 of 26 (88%) patients remained free of clinically significant infections caused by any of six common viruses that posoleucel targets through the Week 14 primary endpoint 3 of 26 (12%) patients had clinically significant infections…